Myriad Genetics Inc (NAS:MYGN)
$ 26.885 0.495 (1.88%) Market Cap: 2.44 Bil Enterprise Value: 2.46 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 78/100

Q2 2021 Myriad Genetics Inc Earnings Call Transcript

Feb 23, 2021 / 09:30PM GMT
Release Date Price: $29.03 (-3.01%)
Operator

Greetings and welcome to the Myriad Genetics December 2020 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, Tuesday, February 23, 2021.

I would now like to turn the conference over to Scott Gleason, VP Investor Relations. Please go ahead.

Scott Gleason
Myriad Genetics, Inc. - SVP of IR

Thank you, Malika. Good afternoon. Welcome to the Myriad Genetics December Quarter 2020 Earnings Call.

During the call, we will review the financial results that we've released today, after which, we'll host a question-and-answer session. If you've not had a chance to review our quarterly earnings release, it can be found on our website at myriad.com.

I am Scott Gleason, the Senior Vice President of Investor Relations and Corporate Strategy. And on the call with me today is Paul Diaz, our President and CEO; and Bryan Riggsbee, our Chief Financial Officer.

This call can be heard live via webcast at myriad.com, and a recording will be archived in the Investors section of our website. In addition, there

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot